We performed further experiments to provide theoretical evidence for UbcH10 and KIAA0101 as therapeutic targets for NSCLC, and the results showed that 4 weeks of intervention had a significant effect on the tumorigenic activity of subcutaneously inoculated NSCLC cells. The gene discussed is UBE2C; the disease is non-small cell lung carcinoma.